CCO Treatment Updates

New Classes of Antiretrovirals: The Clinical Role of Integrase Inhibitors and Entry Inhibitors

New Classes of Antiretrovirals and How They Work

Module 1 of 3

Program Chair:
Joseph J. Eron, Jr., MD

Faculty:
Daniel R. Kuritzkes, MD

CME CREDIT INFORMATION

Release Date: 09/16/07

Expiration Date: 09/15/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Daniel R. Kuritzkes, MD, describes the rationale for development of and clinical data on new classes of antiretroviral agents, entry inhibitors and integrase inhibitors.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize reasons why new antiretroviral agents are needed
Describe modes of action for entry inhibitors and integrase inhibitors
Discuss preclinical proof of concept data for these agents

How, When, and Why to Use Novel Agents

Module 2 of 3

Program Chair:
Joseph J. Eron, Jr., MD

Faculty:
Eric S. Daar, MD

CME CREDIT INFORMATION

Release Date: 09/16/07

Expiration Date: 09/15/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Eric S. Daar, MD, describes clinical data relating to the use of agents in new classes, including the role of these agents in treatment-experienced patients with multidrug resistance.

Learning Objectives

Upon completion of this activity, participants should be able to:

Define the goals of therapy for treatment-experienced patients
Summarize the clinical scenarios that support the use of CCR5 antagonists and integrase inhibitors, based on the clinical data available for these agents
Discuss the advantages and disadvantages related to the use of CCR5 antagonists and integrase inhibitors

Clinical Scenarios for the Use of Novel Agents

Module 3 of 3

Program Chair:
Joseph J. Eron, Jr., MD

Faculty:
Eric S. Daar, MD Daniel R. Kuritzkes, MD

CME CREDIT INFORMATION

Release Date: 09/16/07

Expiration Date: 09/15/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Joseph J. Eron, Jr., MD, guides the reader through the clinical decision-making process that is integral to designing regimens for patients with multidrug-resistant virus.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize goals for treatment of antiretroviral-experienced patients
Discuss the importance of resistance testing in construction of new regimens
Describe criteria that the clinician might use to determine if a particular drug will be active in a patient with multidrug resistance

Animation

The Role of Integrase in the HIV Life Cycle

A 3D animation exploring the role of HIV’s integrase enzyme in the viral lifecycle

Format: Adobe Flash | File size: 12,804 KB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.